{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:56:44Z","timestamp":1791205004233,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1016\/j.parkreldis.2008.04.014","type":"journal-article","created":{"date-parts":[[2008,6,26]],"date-time":"2008-06-26T09:10:33Z","timestamp":1214471433000},"page":"S119-S123","source":"Crossref","is-referenced-by-count":12,"special_numbering":"S2","title":["Role of CYP2E1 in the mouse model of MPTP toxicity"],"prefix":"10.1016","volume":"14","author":[{"given":"Carla","family":"Pardini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Vaglini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Viaggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Caramelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni U.","family":"Corsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2008.04.014_bib1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0165-1781(79)90006-4","article-title":"Chronic parkinsonism secondary to intravenous injection of meperidine analogues","volume":"1","author":"Davis","year":"1979","journal-title":"Psychiat Res"},{"key":"10.1016\/j.parkreldis.2008.04.014_bib2","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1126\/science.6823561","article-title":"Chronic parkinsonism in humans due to a product of meperidine-analog synthesis","volume":"219","author":"Langston","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.parkreldis.2008.04.014_bib3","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1126\/science.6610213","article-title":"Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice","volume":"224","author":"Heikkila","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.parkreldis.2008.04.014_bib4","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/349414a0","article-title":"Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-d-aspartate antagonists","volume":"349","author":"Tursky","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.parkreldis.2008.04.014_bib5","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1073\/pnas.80.14.4546","article-title":"A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","volume":"80","author":"Burns","year":"1983","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.parkreldis.2008.04.014_bib6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0006-8993(86)90905-4","article-title":"Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a neurochemical and morphological reassessment","volume":"376","author":"Ricaurte","year":"1986","journal-title":"Brain Res"},{"key":"10.1016\/j.parkreldis.2008.04.014_bib7","first-page":"285","article-title":"A model for chronic neurotoxicity: long-term retention of the neurotoxin 1-methyl-4-phenyl-pyridinium (MPP+) within catecholaminergic neurons","volume":"12","author":"Johannessen","year":"1991","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.parkreldis.2008.04.014_bib8","first-page":"333","article-title":"Mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced destruction of dopaminergic neurons","volume":"vol. 102","author":"Kopin","year":"1992"},{"key":"10.1016\/j.parkreldis.2008.04.014_bib9","first-page":"321","article-title":"Molecular and cellular events regulating dopamine neuron survival","volume":"vol. 154","author":"Corsini","year":"2002"},{"key":"10.1016\/j.parkreldis.2008.04.014_bib10","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/0006-291X(84)91293-2","article-title":"Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase","volume":"120","author":"Chiba","year":"1984","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.parkreldis.2008.04.014_bib11","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/311464a0","article-title":"Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism","volume":"311","author":"Markey","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.parkreldis.2008.04.014_bib12","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/0024-3205(85)90146-8","article-title":"Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","volume":"36","author":"Nicklas","year":"1985","journal-title":"Life Sci"},{"key":"10.1016\/j.parkreldis.2008.04.014_bib13","doi-asserted-by":"crossref","first-page":"7885","DOI":"10.1016\/S0021-9258(19)57434-8","article-title":"Energy-dependent uptake of 1-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria","volume":"261","author":"Ramsay","year":"1986","journal-title":"J Biol Chem"},{"key":"10.1016\/j.parkreldis.2008.04.014_bib14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0014-2999(85)90331-0","article-title":"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by pretreatment with diethyldithiocarbamate","volume":"119","author":"Corsini","year":"1985","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.parkreldis.2008.04.014_bib15","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0024-3205(87)90030-0","article-title":"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by ethanol or acetaldehyde","volume":"40","author":"Corsini","year":"1987","journal-title":"Life Sci"},{"key":"10.1016\/j.parkreldis.2008.04.014_bib16","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/0024-3205(87)90300-6","article-title":"4-Phenylpyridine (4PP) and MPTP: the relationship between striatal MPP+ concentrations and neurotoxicity","volume":"40","author":"Irwin","year":"1987","journal-title":"Life Sci"},{"key":"10.1016\/j.parkreldis.2008.04.014_bib17","first-page":"691","article-title":"Correlation between the neostriatal content of the 1-methyl-4-phenyl-pyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice","volume":"257","author":"Giovanni","year":"1991","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.parkreldis.2008.04.014_bib18","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1006\/exnr.1994.1079","article-title":"In Brown Norway rats, MPP+ is accumulated in nigrostriatal dopaminergic terminals but it is not neurotoxic: a model of neural resistance to MPTP toxicity","volume":"127","author":"Zuddas","year":"1994","journal-title":"Exp Neurol"},{"key":"10.1016\/j.parkreldis.2008.04.014_bib19","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/glia.440050108","article-title":"Production and disposition of 1-methyl-4-phenylpyridinium in primary cultures of mouse astrocytes","volume":"5","author":"Di Monte","year":"1992","journal-title":"Glia"},{"key":"10.1016\/j.parkreldis.2008.04.014_bib20","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/BF00165297","article-title":"The extraneuronal transport mechanism for noradrenaline (uptake 2) avidly transports 1-methyl-4-phenylpyridinium (MPP+)","volume":"346","author":"Russ","year":"1992","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.parkreldis.2008.04.014_bib21","first-page":"1000","article-title":"Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Part 1: systemic administration","volume":"270","author":"Giovanni","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.parkreldis.2008.04.014_bib22","first-page":"1008","article-title":"Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 2: central administration of 1-methyl-4-phenylpyridinium","volume":"270","author":"Giovanni","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.parkreldis.2008.04.014_bib23","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1006\/neur.1996.0019","article-title":"Striatal MPP+ levels do not necessarily correlate with striatal dopamine levels after MPTP treatment in mice","volume":"5","author":"Vaglini","year":"1994","journal-title":"Neurodegeneration"},{"key":"10.1016\/j.parkreldis.2008.04.014_bib24","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/0006-8993(89)91083-4","article-title":"Xenobiotic metabolism in human brain presence of cytochrome P-450 and associated mono-oxygenases","volume":"496","author":"Ravindranath","year":"1989","journal-title":"Brain Res"},{"key":"10.1016\/j.parkreldis.2008.04.014_bib25","article-title":"Cytochrome P450 enzymes in brain","volume":"vol. 22","author":"Warner","year":"1994"},{"key":"10.1016\/j.parkreldis.2008.04.014_bib26","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0306-4522(97)00649-0","article-title":"Co-localization of P450 enzymes in the rat substantia nigra with tyrosine hydroxylase","volume":"86","author":"Watts","year":"1998","journal-title":"Neuroscience"},{"key":"10.1016\/j.parkreldis.2008.04.014_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0163-7258(90)90032-W","article-title":"Mechanism of ethanol induced hepatic injury","volume":"46","author":"Lieber","year":"1990","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.parkreldis.2008.04.014_bib28","series-title":"Casarett and Doull's toxicology: the basic science of poison","first-page":"113","article-title":"Biotransformation of xenobiotics","author":"Parkinson","year":"1996"},{"key":"10.1016\/j.parkreldis.2008.04.014_bib29","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1177\/096032719701600505","article-title":"Low-dose diethyldithiocarbamate attenuates the hepatotoxicity of 1,3-dichloro-2-propanol and selectively inhibits CYP2E1 activity in the rat","volume":"16","author":"Stott","year":"1997","journal-title":"Hum Exp Toxicol"},{"key":"10.1016\/j.parkreldis.2008.04.014_bib30","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1471-4159.2004.02720.x","article-title":"Involvement of cytochrome P450 2E1 in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease","volume":"91","author":"Vaglini","year":"2004","journal-title":"J Neurochem"},{"key":"10.1016\/j.parkreldis.2008.04.014_bib31","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0014-2999(87)90265-2","article-title":"The effect of diethyldithiocarbamate on the biodisposition of MPTP: an explanation for enhanced neurotoxicity","volume":"141","author":"Irwin","year":"1987","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.parkreldis.2008.04.014_bib32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0006-8993(89)91021-4","article-title":"Acetaldehyde directly enhances MPP+ neurotoxicity and delays its elimination from the striatum","volume":"501","author":"Zuddas","year":"1989","journal-title":"Brain Res"},{"key":"10.1016\/j.parkreldis.2008.04.014_bib33","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1046\/j.1471-4159.2003.01773.x","article-title":"Increased synaptosomal dopamine content and brain concentration of paraquat produced by selective dithiocarbamates","volume":"85","author":"Barlow","year":"2003","journal-title":"J Neurochem"},{"key":"10.1016\/j.parkreldis.2008.04.014_bib34","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S0022-3565(24)38836-6","article-title":"Protein tyrosine kinase inhibitors alter human dopamine transporter activity in xenopus oocytes","volume":"296","author":"Doolen","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.parkreldis.2008.04.014_bib35","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/0003-9861(90)90741-G","article-title":"The dopamine transporter and cytochrome P45OIID1 (debrisoquine 4-hydroxylase) in brain: resolution and identification of two distinct [3H]GBR-12935 binding proteins","volume":"276","author":"Niznik","year":"1990","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.parkreldis.2008.04.014_bib36","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S0169-409X(02)00167-9","article-title":"Pharmacogenetics of CYP enzymes and drug transporters: remarkable recent advances","volume":"54","author":"Kim","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.parkreldis.2008.04.014_bib37","doi-asserted-by":"crossref","first-page":"12063","DOI":"10.1074\/jbc.271.20.12063","article-title":"Role of CYP2E1 in the hepatotoxicity of acetaminophen","volume":"271","author":"Lee","year":"1996","journal-title":"J Biol Chem"},{"issue":"Suppl","key":"10.1016\/j.parkreldis.2008.04.014_bib38","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/978-3-211-45295-0_27","article-title":"Cytochrome P450 and Parkinson's disease: protective role of neuronal CYP 2E1 from MPTP toxicity","volume":"70","author":"Viaggi","year":"2006","journal-title":"J Neural Transm"}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802008001259?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802008001259?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T21:28:20Z","timestamp":1738272500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802008001259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":38,"alternative-id":["S1353802008001259"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2008.04.014","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2008,7]]}}}